Time filter

Source Type

Quaranta L.,University of Brescia | Riva I.,University of Brescia | Katsanos A.,University of Ioannina | Floriani I.,Laboratory of Clinical Research | Centofanti M.,University of Rome Tor Vergata
Clinical Ophthalmology

Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP. © 2015 Leung et al. Source

Quaranta L.,University of Brescia | Riva I.,University of Brescia | Floriani I.C.,Laboratory of Clinical Research
European Journal of Ophthalmology

Purpose: To evaluate the long-term outcomes of a surgical technique using a sutureless bovine pericardial patch graft for the implantation of an Ahmed glaucoma valve (AGV). Methods: This was a pilot study on patients with primary open-angle glaucoma refractory to repeated surgical filtering procedures. All patients underwent AGV implant technique using a sutureless bovine pericardial patch graft. The pericardial membrane was cut using an ordinary corneal trephine with a diameter of 9.0 or 10.0 mm. The anterior part of the tube was covered with the graft and kept in place with fibrin glue. Subsequently, the cap was stitched all around the tube and the dissected conjunctiva was laid over it. Intraocular pressure (IOP) and complications were evaluated 1 week and 1, 3, 6, 12, and 24 months after surgery. Results: The procedure was used to treat 20 eyes of 20 consecutive patients (12 men and 8 women: mean age [SD] 64.8 [7.8] years). Mean IOP was 28.1 mm Hg (SD 4.9) at baseline and decreased to 14.9 mm Hg (SD 1.5) 24 months after surgery (p<0.001). The overall mean number of topical medications was 3.1 (SD 0.5) at baseline and decreased to 1.4 (SD 0.8) after 24 months (p<0.001). During follow-up, there was no conjunctival erosion, thinning of pericardial patch graft over the tube, or tube exposure; no signs of endophthalmitis were recorded. Conclusions: The results suggest that the sutureless technique using a bovine pericardial graft patch is a safe and rapid procedure for AGV implantation. © 2013 Wichtig Editore. Source

Quaranta L.,University of Brescia | Riva I.,University of Brescia | Floriani I.C.,Laboratory of Clinical Research
European Journal of Ophthalmology

Purpose: To evaluate the outcomes of conjunctival compression sutures (CCS) for enlarged overfilte-ring blebs associated with ocular hypotony after uncomplicated trabeculectomy with mitomycin C (TM). Methods: A retrospective analysis of consecutively recruited patients with enlarged conjunctival bleb associated with hypotony who had undergone CCS was performed. Patients were considered for CCS if they had enlarged overfiltering bleb for at least 4 weeks, following an uncomplicated TM, with no sign of resolution. Only patients with hypotony, defined as intraocular pressure (IOP) <6 mm Hg associated with a reduced vision of at least 2 lines, were included. Success was defined as an IOP >6 mm Hg 6 months after surgery. results: A total of 45 eligible patients were identified. In 29 eyes of 45 patients (64.4%), success in providing resolution of the preexisting hypotony (postoperative IOP mean ± standard deviation 13.4 ± 1.8 mm Hg, range 10-16 mm Hg) was obtained. Out of these 29 eyes, 9 eyes had a conjunctival bleb diffusion over 180 degrees, 19 eyes overfiltering bleb over 270 degrees, and 1 eye over 360 degrees. Complications from CCS included a transient spike of IOP in the first postoperative week (8 patients); a bleb rupture associated with conjunctival leaks and hypotony was observed in one eye. conclusions: The placement of CCS is a safe and effective technique for managing overfiltering blebs associated with hypotony. The present study suggests that CCS are not effective for dealing with cir-cumferential blebs extending over 360 degrees. © 2013 Wichtig Editore. Source

Schussler O.,University of Ottawa | Schussler O.,Biosurgery Laboratory | Chachques J.C.,University of Ottawa | Mesana T.G.,Biosurgery Laboratory | And 4 more authors.
Asian Cardiovascular and Thoracic Annals

Experimental studies in animals and recent human clinical trials have revealed the current limitations of cellular transplantation, which include poor cell survival, lack of cell engraftment, and poor differentiation. Evidence in animals suggests that use of a 3-dimensional scaffold may enhance cell therapy and engineer myocardial tissue by improving initial cell retention, survival, differentiation, and integration. Several scaffolds of synthetic or natural origin are under development. Until now, contractility has been demonstrated in vitro only in biological scaffolds prepared from decellularized organs or tissue, or in collagenic porous scaffold obtained by crosslinking collagen fibers. While contractility of a cellularized collagen construct is poor, it can be greatly enhanced by tumor basement membrane extract. Recent advances in biochemistry have shown improved cell-matrix interactions by coupling adhesionmolecules to achieve an efficient and safe bioartificial myocardium with no tumoral component. Fixation of adhesion molecules may also be a way to enhance cell homing and/or differentiation to increase local angiogenesis. Whatever the clinically successful combination ultimately proves to be, it is likely that cell therapy will require providing a supportive biochemical, physical, and spatial environment that will allow the cells to optimally differentiate and integrate within the target myocardial tissue. © SAGE Publications 2010. Source

Bhatnagar I.,Pukyong National University | Bhatnagar I.,Laboratory of Clinical Research | Thomas N.V.,Pukyong National University | Kim S.-K.,Pukyong National University
Anti-Cancer Agents in Medicinal Chemistry

Cancer has long been an area of extensive research both at the molecular as well as pharmaceutical level. However, lack of understanding of the underlying molecular signalling and the probable targets of therapeutics is a major concern in successful treatment of cancer. The situation becomes even worse, with the increasing side effects of the existing synthetic commercial drugs. Natural compounds especially those derived from plants have been best explored for their anticancer properties and most of them have been efficient against the known molecular targets of cancer. However, advent of biotechnology and resulting advances in medical arena have let to the increasing knowledge of newer carcinogenic signaling agents which has made the anticancer drug discovery even more demanding. The present review aims to bring forward the molecular mediators of cancer and compiles the plant derived anticancer agents with special emphasis on their clinical status. Since marine arena has proved to be a tremendous source of pharmaceutical agents, this review also focuses on the anticancer potential of marine plants especially algae. This is a comprehensive review covering major aspects of cancer mediation and utilization of marine flora for remediation of this deadly disease. © 2013 Bentham Science Publishers. Source

Discover hidden collaborations